Omivera B.V.

Omivera B. V. , based in Leiden, Netherlands, specializes in drug development through its innovative CellEKT platform, which enhances the analysis of kinase selectivity and target engagement in living cells for pharmaceutical and biotechnology companies. Omivera B.

V. operates a specialized platform focused on kinase selectivity and target engagement assessment. The company was formed to support drug discovery and development processes. Located at the Leiden Bio Science Park, Omivera is positioned within a prominent life sciences hub in Europe.

TIn February 2026, Omivera B. V. raised EUR 350,000 in seed funding from InnovationQuarterOmivera offers CellEKT, a specialized platform designed to assess kinase selectivity and target engagement in living cells. Utilizing proprietary molecular probes and advanced proteomics techniques, CellEKT measures interactions with over 90% of the expressed kinome and various potential non-kinase off-targets.

This technology primarily serves pharmaceutical and biotechnology companies focused on drug discovery, providing tailored services that enhance drug development pipelines by profiling kinase inhibitors and identifying molecular targets responsible for biological effects. Omivera generates revenue through its CellEKT platform, offered as a contract research organization (CRO) service to pharmaceutical and biotech partners. The company engages clients in service agreements for comprehensive data analysis concerning drug selectivity and target engagement. Revenue is derived from fees associated with individualized studies or service packages, reflecting a B2B transaction structure.

The recurring revenue potential is bolstered by ongoing collaborations, with pricing influenced by assay complexity and data depth provided to partners. In February 2026, Omivera B. V. raised an undisclosed amount of seed funding from InnovationQuarter to support the development of its CellEKT technology.

The company is focused on enhancing this platform and expanding its reach in the pharmaceutical and biotechnology sectors. Future strategies include exploring new geographic markets, aiming for a broader presence in Europe and North America, to be implemented by the end of 2026.